Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T.

Cancer Chemother Pharmacol. 2018 Feb;81(2):291-304. doi: 10.1007/s00280-017-3495-2. Epub 2017 Dec 4.

PMID:
29204687
2.

New ligands of the ghrelin receptor based on the 1,2,4-triazole scaffold by introduction of a second chiral center.

Maingot M, Blayo AL, Denoyelle S, M'Kadmi C, Damian M, Mary S, Gagne D, Sanchez P, Aicher B, Schmidt P, Müller G, Teifel M, Günther E, Marie J, Banères JL, Martinez J, Fehrentz JA.

Bioorg Med Chem Lett. 2016 May 15;26(10):2408-2412. doi: 10.1016/j.bmcl.2016.04.003. Epub 2016 Apr 4.

PMID:
27072910
3.

New trisubstituted 1,2,4-triazoles as ghrelin receptor antagonists.

Blayo AL, Maingot M, Aicher B, M'Kadmi C, Schmidt P, Müller G, Teifel M, Günther E, Gagne D, Denoyelle S, Martinez J, Fehrentz JA.

Bioorg Med Chem Lett. 2015 Jan 1;25(1):20-4. doi: 10.1016/j.bmcl.2014.11.031. Epub 2014 Nov 15.

PMID:
25435152
4.

Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.

Defaux J, Antoine M, Logé C, Le Borgne M, Schuster T, Seipelt I, Aicher B, Teifel M, Günther E, Gerlach M, Marchand P.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3748-52. doi: 10.1016/j.bmcl.2014.06.078. Epub 2014 Jul 3.

PMID:
25022204
5.

Current view on the mechanism of action of perifosine in cancer.

Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J.

Anticancer Agents Med Chem. 2014 May;14(4):629-35. Review.

PMID:
24628236
6.

Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.

Defaux J, Antoine M, Le Borgne M, Schuster T, Seipelt I, Aicher B, Teifel M, Günther E, Gerlach M, Marchand P.

ChemMedChem. 2014 Jan;9(1):217-32. doi: 10.1002/cmdc.201300384. Epub 2013 Nov 24.

PMID:
24273104
7.

Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.

Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P, Michel MS.

Oncol Rep. 2009 Aug;22(2):321-6.

PMID:
19578772
8.

Development of AEZS-115 (ZEN-019) by optimization of structurally unique, orally active, peptidomimetic GnRH antagonists.

Paulini KW, Baasner S, Gerlach M, Polymeropoulos EE, Schmidt P, Schuster T, Teifel M, Guenther EG.

Adv Exp Med Biol. 2009;611:521-2. No abstract available.

PMID:
19400294
9.

Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.

Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M.

Clin Cancer Res. 2008 Jul 15;14(14):4603-11. doi: 10.1158/1078-0432.CCR-07-4738.

10.

Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes.

Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M.

Int J Cancer. 2008 Jan 15;122(2):452-60.

11.

Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting.

Eichhorn ME, Luedemann S, Strieth S, Papyan A, Ruhstorfer H, Haas H, Michaelis U, Sauer B, Teifel M, Enders G, Brix G, Jauch KW, Bruns CJ, Dellian M.

Cancer Biol Ther. 2007 Jun;6(6):920-9. Epub 2007 Mar 26.

PMID:
17534143
12.

Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.

Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch KW, Dellian M.

Cancer Biol Ther. 2006 Jan;5(1):89-96. Epub 2006 Jan 22.

PMID:
16357513
13.

Morphology and transfection study of human microvascular endothelial cell angiogenesis: an in vitro three-dimensional model.

Lienau J, Kaletta C, Teifel M, Naujoks K, Bhoola K, Plendl J.

Biol Chem. 2005 Feb;386(2):167-75.

PMID:
15843161
14.

Protamine enhances uptake of cationic liposomes in angiogenic microvessels.

Eichhorn ME, Strieth S, Krasnici S, Sauer B, Teifel M, Michaelis U, Naujoks K, Dellian M.

Angiogenesis. 2004;7(2):133-41.

PMID:
15516834
15.

Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature.

Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M.

Int J Cancer. 2004 May 20;110(1):117-24.

16.

Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy.

Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M.

Clin Cancer Res. 2003 Jun;9(6):2335-41.

17.

Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels.

Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M.

Int J Cancer. 2003 Jul 1;105(4):561-7.

18.

Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.

Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P.

J Invest Dermatol. 2003 Mar;120(3):476-82.

20.
21.

Optimization of transfection of human endothelial cells.

Teifel M, Heine LT, Milbredt S, Friedl P.

Endothelium. 1997;5(1):21-35.

PMID:
9142319
22.
23.

New lipid mixture for efficient lipid-mediated transfection of BHK cells.

Teifel M, Friedl P.

Biotechniques. 1995 Jul;19(1):79-80, 82.

PMID:
7669301

Supplemental Content

Loading ...
Support Center